Study #2018-1008
Radioembolization for HCC Patients with Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)
MD Anderson Study Status
Not Accepting
Treatment Agent
Description
This trial aims to improve hepatocellular carcinoma (HCC) tumor responses in patients undergoing Y90 radioembolization by using personalized dosimetry as part of treatment planning. Using standard calculations for Y90 doses may not be specific enough for individual patients given that there can be differences in how tumor cells and liver cells respond to radiation. Personalized dose plans may help improve treatment and outcomes in liver cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Stage III Hepatocellular Carcinoma AJCC v8;Stage IIIA Hepatocellular Carcinoma AJCC v8;Stage IIIB Hepatocellular Carcinoma AJCC v8;Stage IV Hepatocellular Carcinoma AJCC v8;Stage IVA Hepatocellular Carcinoma AJCC v8;Stage IVB Hepatocellular Carcinoma AJCC v8;Unresectable Hepatocellular Carcinoma
Study phase:
Not applicable
Physician name:
Armeen Mahvash
Department:
Interventional Radiology
For general questions about clinical trials:
1-866-671-2559
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.